Market Scenario:
Bile duct cancer or
cholangiocarcinoma is a form of cancer in which epithelial cells are mutated,
i.e., they show epithelial differentiation in the bile duct. It is a type of
rare neoplasm. According to the National Cancer Institute, in 2014, there were
an estimated 66,771 people living with liver and intrahepatic bile duct cancer
in the United States. Moreover, the disease is expected to cause 28,920 deaths
by the end of 2017 accounting for 4.8% of all cancer deaths. Rates for new
liver and intrahepatic bile duct cancer cases have risen by an average 2.7%
each year over the last 10 years. Death rates have been estimated to have risen
by an average of 2.6% each year over 2005-2014. Such an increase in the
prevalence of bile duct cancer has boosted the market. Additionally, rising
healthcare expenditures, increasing awareness for the disease and investments
in the R&D for treatment procedures is fuelling the market further.
However, high cost of treatment and related side effects along with low
healthcare expenditures in the developing economies is expected to restrain the
market during the forecasted period.
The global bile duct cancer
market is expected to grow at an approximate CAGR of 9.2% during the forecast
period.
Segmentation
The global bile duct cancer market is segmented on
the basis of types, diagnosis, treatment, and end users.
On the basis of types, the market is segmented into
intrahepatic, extrahepatic, and others.
On the basis of diagnosis, the market is segmented
into blood tests, abdominal imaging, surgery, and others. The diagnosis segment
by abdominal imaging is sub segmented into endoscopic retrograde
cholangiopancreatography (ERCP), percutaneous transhepatic cholangiography
(PTC), magnetic resonance cholangiopancreatography (MRCP), and others.
On the basis of treatment, the market is segmented
into chemotherapy, radiotherapy, and others. The chemotherapy segment is sub
segmented into 5-fluorouracil, gemcitabine, cisplatin, and others.
On the basis of end users, the market is segmented
into hospital &clinics, academic institutes, research organizations and
others.
Regional Analysis
The Americas dominates the global bile duct cancer market owing to a well-developed
healthcare sector. Apart from this, increasing number of patients, increasing
healthcare expenditure have boosted the growth of the market in the Americas.
According to the Centers for Disease Control and Prevention, U.S. health care
spending in 2015, reached $3.2 trillion or $9,990 per person which accounted
for 17.8% of the total GDP.
Europe is the second largest bile duct cancer
market, which is followed by Asia Pacific. Availability of funds for research,
huge patient population and government support for research & development
drives the European market.
Asia Pacific is the fastest growing region for the
market due to the presence of a huge patient population, continuously
developing economies like India and China, and presence of huge opportunity in
the market. According to Indian Brand Equity Fund, the per capita healthcare
expenditure in India is estimated to grow at a CAGR of 5% during 2008-15 and
reach USD 68.6 by 2015.
Key
players for global bile duct cancer market
The key players for the global bile duct
cancer market are Pfizer Inc. (U.S.), F. Hoffmann-La Roche Ltd
(Europe), Bristol-Myers Squibb Company (U.S.), Teva Pharmaceutical Industries
Ltd. (Middle East), Eli Lilly and Company. (U.S.), Sanofi (Europe),
Fresenius Kabi AG (Europe), Mylan N.V. (U.S.), and others.
Detailed Table
of Contents:
1. Report
Prologue
2. Market
Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
3. Research
Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size
Estimation
4. Market
Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends
& Assessment
5. Market
Factor Analysis
…
Continued!
About US:
Market Research
Future (MRFR), enable customers to unravel the complexity of various industries
through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw
Research Reports (3R), Continuous-Feed Research (CFR), and Market Research
& Consulting Services.
Contact Us:
Market Research
Future
Office No. 528,
Amanora Chambers
Magarpatta Road,
Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845
9312
Email:
sales@marketresearchfuture.com
